Pharmacology of moquizone, a new choleretic drug.
D000818:Animals; D001646:Bile / Q000378:metabolism; D001647:Bile Acids and Salts / Q000032:analysis; D001663:Bilirubin / Q000032:analysis; D002415:Cats; D002756:Cholagogues and Choleretics / Q000494:pharmacology*; D002784:Cholesterol / Q000032:analysis; D003685:Dehydrocholic Acid / Q000494:pharmacology; D004231:Diuresis / Q000187:drug effects; D004285:Dogs; D004386:Duodenum; D005704:Gallbladder / Q000187:drug effects; D006168:Guinea Pigs; D006439:Hemodynamics / Q000187:drug effects; D007267:Injections; D007275:Injections, Intravenous; D007928:Lethal Dose 50; D051379:Mice; D009025:Morpholines / Q000008:administration & dosage / Q000494:pharmacology / Q000633:toxicity; D009130:Muscle, Smooth / Q000187:drug effects; D011799:Quinazolines / Q000008:administration & dosage / Q000494:pharmacology* / Q000633:toxicity; D011817:Rabbits; D051381:Rats; D013752:Tetracycline / Q000378:metabolism
D001647:Bile Acids and Salts; D002756:Cholagogues and Choleretics; D009025:Morpholines; D011799:Quinazolines; D002784:Cholesterol; D013752:Tetracycline; D003685:Dehydrocholic Acid; D001663:Bilirubin